INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Volume 11, Number 6 • June 1990

EDITORIAL

***Clostridium difficile* Colitis in the Hospital Setting: A Potentially Explosive Problem** 281
Charles W. Stratton, MD

ORIGINAL ARTICLES

Risk Factors for *Clostridium difficile* Toxin-Associated Diarrhea 283
Elizabeth Brown, MD; George H. Talbot, MD; Peter Axelrod, MD; Mary Provencher, MT (ASCP); Cindy Hoegg, RN

Methicillin-Resistant *Staphylococcus aureus* Outbreak at a Veterans' Affairs Medical Center: Importance of Carriage of the Organism by Hospital Personnel 291
Annette C. Reboli, MD; Joseph F. John, Jr., MD; Christel G. Platt, RN; J. Robert Cantey, MD

Intravascular Catheter Colonization and Related Bloodstream Infection in Critically Ill Neonates 301
Wendy A. Cronin, MS, MT (ASCP); Teresa P. Germanson, MS, MPH; Leigh G. Donowitz, MD

SPECIAL COMMENTARY

Strategies for the Management of Varicella-Susceptible Healthcare Workers After a Known Exposure 309
Adele Josephson, PhD, MPH, CIC; Lynne Karanfil, RN, MA, CIC; Myles E. Gombert, MD

TOPICS IN CLINICAL MICROBIOLOGY

Human T-Cell Lymphotropic Virus Type-I 314
Julie Larkin, BA; John T. Sinnott, IV, MD; Joshua Weiss, BS; Douglas A. Holt, MD

CLINICAL PHARMACOLOGY OF ANTIBIOTICS

Pharmacodynamic Properties of Antibiotics: Application to Drug Monitoring and Dosage Regimen Design 319
Steven C. Ebert, PharmD; William A. Craig, MD

LETTERS TO THE EDITOR

Prevalence of Toxoplasmosis Among a Sample of Pregnant Women in Risafa, Baghdad 279
A.A. Abood, MD; S. Abbas; A. Muala; W. Syrop

Sterilization Container Systems 279
Nathan L. Belkin, PhD
(Reply) Peggy Ryan, RN

SHEA NEWSLETTER 327

SPECIAL ANNOUNCEMENT

Preliminary Program of the Centers for Disease Control's Third Decennial International Conference on Nosocomial Infections, July 31-August 3, 1990 297

The Official Journal of The Society of Hospital Epidemiologists of America

https://doi.org/10.1086/646169 Published online by Cambridge University Press

From SmithKline Biologicals/
Smith Kline &French Laboratories

Engerix-B®

Hepatitis B Vaccine (Recombinant)

0, 1, 2 Month Dosing Regimen for Certain Populations*

20 mcg recombinant dose helps to ensure immune response in adult patients of all ages

Choice of dosing regimens

Adult dose (mcg)
Standard dosing regimen (0, 1 and 6 months)
New 0, 1, 2 month dosing regimen for certain populations*
Published efficacy data: Neonates born of infected mothers'
VACTRAC™—computer software for vaccination tracking and compliance
Bar-coded, unit-dose vials
Lowest cost per dose[2]

*For those recently exposed to the virus (including needlestick exposure), certain travelers to high-risk areas, and neonates born of infected mothers. When prolonged maintenance of protective antibody titers is desired, a booster dose at month 12 is recommended.

†Hepatitis B Vaccine (Recombinant), MSD.

‡Please see brief summary of prescribing information on adjacent page for a complete listing of adverse reactions, contraindications, warnings and precautions.

©SmithKline Beckman Corporation, 1990

https://doi.org/10.1086/646169 Published online by Cambridge University Press

Lowest Cost Per Dose[2]

Extensively Tested and Well Tolerated‡


State-of-the-art recombinant technology

14 million doses distributed in over 87 countries[3]

Switch to 'Engerix-B'

Can be used to complete a course of vaccination initiated with another hepatitis B vaccine[3,4]

Engerix-B®	Recombivax HB®†
20	10
Yes	Yes
Yes	No
Yes	Yes
Yes	No
Yes	No
Yes	No



Manufactured by
SmithKline Biologicals
Rixensart, Belgium

Distributed by
Smith Kline & French Laboratories
Philadelphia, PA 19101

https://doi.org/10.1086/646169 Published online by Cambridge University Press

Engerix-B®

Hepatitis B Vaccine (Recombinant)

See complete prescribing information in SK&F literature or *PDR*. The following is a brief summary.

INDICATIONS AND **USAGE:** 'Engerix-B' is indicated for immunization against infection caused by all known subtypes of hepatitis B virus Immunization is recommended in persons of all ages, especially those who are. or will be. at increased risk of exposure to hepabbs B virus

CONTRAINDICATIONS: Hypersensitivity to yeast or any other component of the vaccine is a contraindication for use of the vaccine

WARNINGS: Do not give additional injections to patients experiencing hypersensitivity after an 'Engerix B' injection. (See CONTRAINDICATIONS)

Hepatitis B has a long incubation period Hepatitis B vaccination may not prevent hepatitis B infection in individuals who had an unrecognized hepabbs B infection at the time of vaccine administration Additionally, it may not prevent infection in individuals who do not achieve protective antibody titers

PRECAUTIONS: **General:** As with any percutaneous vaccine, keep epinephrine available for use in case of anaphylaxis or anaphylactoid reaction.

As with any vaccine, delay administration, if possible, in persons with any febrile illness or active infection

Pregnancy: Pregnancy Category C. Animal reproduction studies have not been conducted with 'Engerix-B' It is also not known whether 'Engerix-B' can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Give 'Engerix-B' to a pregnant woman only if clearly needed.

Nursing Mothers: It is not known whether 'Engerix-B' is excreted in human milk Because many drugs are excreted in human milk, use caution when giving 'Engerix-B' to a nursing woman.

Pediatric Uu: 'Engerix-B' has been shown to be well tolerated and highly immunogenic in infants and children of all ages Newborns also respond well; maternally transferred antibodies do not interfere with the active immune response to the vaccine

ADVERSE REACTIONS: 'Engerix-B' is generally well tolerated During clinical studies involving over 10,000 individuals distributed over all age groups, no serious adverse reactions attributable to vaccine administration were reported As with any vaccine however it is possible that expanded commercial use of the vaccine could weal rare adverse reactions not observed in clinical studies.

Ten double-blind studies involving 2,252 subjects showed no significant difference in the frequency or severity of adverse experiences between 'Engerix B' and plasma-dewed vaccines In 36 clinical studies a total of 13,495 doses of 'Engenx-B were administered to 5,071 healthy adults and children who were initially seronegative for hepatitis B markers, and healthy neonates All subjects were monitored for 4 days post-administration Frequency of adverse experiences tended to decrease with successive doses of 'Engerix-B'. Using a symptom checklist,' the most frequently reported adverse reactions were injection site soreness (22%), and fatigue* (14%) Other reactions are listed below:

Incidence 1% Ia **10% of Injections:** Induration: erythema; swelling; fever (> 37 5°C), headache': dizziness.*

'Parent or guardian completed forms for children and neonates Neonatal checklist did not include headache, fatigue or dizziness

Incidence < 1% of Injections: Pain; pruritus; ecchymosis; sweating; malaise chills; weakness, flushing; tingling; hypotension; influenza-like symptoms, upper respiratory tract illnesses; nausea: anorexia; abdominal pain/cramps. vomiting; constipation; diarrhea; lymphadenopathy; pain/stiffness in arm, shoulder or neck. arthralgia; myalgia, back pain; rash, urticaria; petechiae; erythema; somnolence. insomnia; irritability; agitation

Additional adverse experiences have been reported with the commercial use of 'Engerix B' outside the United Stales Those listed below are to serve as alerting information to physicians Anaphylaxis; erythema multiforme including Stevens-Johnson syndrome; angioedema; arthritis; tachycardia/palpitations; bronchospasm including asthma-like symptoms; abnormal liver function tests migraine; syncope; paresis; neuropathy including hypoesthesia, paresthesia, Guillain-Barré syndrome and Bell's palsy. transverse myelitis; thrombocytopenia; eezema; purpura, herpes zoster; vertigo; conjunctivitis; keratitis; visual disturbances

Potential Adverse Experiences In addition, certain other adverse experiences not observed with 'Engerix-B' have been reported with Heptavax-B®† and/or Recombivax HB®‡ Those listed below are to serve as alerting information to physicians: Optic neuritis

HOW **SUPPLIED:** 20 mcg/mL in Single-Dose Vials in packages of 1. 10 and 25 vials

NDC 0007-3860-01 (package of 1)
NDC 0007-3860-11 (package of 10)
NDC 0007-3860-16 (package of 25)

10 mcg/0 5 mL in Single-Dose Vials in packages of 1 vial

NDC 0007-3859-01 (package of 1)

† plasma-derived Hepatitis B Vaccine. MSD
‡ yeast-derived, Hepatitis B Vaccine, MSD

Manufactured by **SmithKline Biologicals**, Rixensart, Belgium
Distributed by **Smith Kline & French Laboratories**
Division of SmithKline Beckman Corp Philadelphia, PA 19101

Date of issuance Aug. 1989

BRS-EB L6

© SmithKline Beckman Corporation, 1989

Engerix-B is a registered trademark of SmithKline Beckman Corporation.

References:
1. Poovorawan Y, Sanpavat S, Pongpunlert W, et al: Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. *JAMA 1989;* 261(22):3278–3281.
2 Based on Medi-Span® Hospital Formulary Pricing Guide, December 1989. 3. Damon file, SK&F 4. Bush L, Moonsammy G, Boscia J: Evaluation of initiating a hepatitis B vaccination schedule with one vaccine and completing it with another. *Hepatology* 1989;10:689.

HATS OFF TO FIRST CLASS SERVICE

At SLACK Incorporated we believe our subscribers are first class people. That's why we do everything possible to publish first class journals. And, that's why we maintain a TOLL-FREE CUSTOMER SERVICE HOTLINE. For the first class customer service you deserve, call:

1-800-257-8290


Talk to a SLACK Customer Service Representative about:

Subscriptions. Subscribing by phone is quick and easy; it only takes a minute and Visa and Mastercard are accepted.

Renewals. Early subscription renewal helps avoid possible interruptions in service.

Change of Address. Please notify us four weeks in advance to assure prompt delivery to your new address.

Questions or Problems. Delivery problems or questions about your subscriptions can be handled instantly.



SLACK

6900 Grove Road,
Thorofare, NJ 08086

https://doi.org/10.1086/646169 Published online by Cambridge University Press

VOLUME 11, NUMBER 6 JUNE 1990

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

EDITORIAL

***Clostridium diflicile Colitis* in the Hospital Setting: A Potentially Explosive Problem** 281
Charles W. Stratton, MD

ORIGINAL ARTICLES

Risk Factors for *Clostridium difficile* Toxin-Associated Diarrhea *283*
Elizabeth Brown, MD; George H. Talbot, MD; Peter Axelrod, MD; Mary Provencher, MT (ASCP); Cindy Hoegg, RN

Methicillin-Resistant *Staphylococcus aureus* Outbreak at a Veterans' Affairs Medical Center: Importance of Carriage of the Organism by Hospital Personnel *291*
Annette C. Reboli, MD; Joseph F. John, Jr., MD; Christel G. Platt, RN; J. Robert Cantey, MD

Intravascular Catheter Colonization and Related Bloodstream Infection in Critically Ill Neonates *301*
Wendy A. Cronin, MS, MT (ASCP); Teresa P. Germanson, MS, MPH; Leigh G. Donowitz, MD

SPECIAL SECTIONS

Special Commentary **309**
Strategies for the Management of Varicella-Susceptible Healthcare Workers After a Known Exposure
Adele Josephson, PhD, MPH, CIC; Lynne Karanfil, RN, MA, CIC; Myles E. Gombert, MD

Topics in Clinical Microbiology 314
Human T-Cell Lymphotropic Virus Type-I
Julie Larkin, BA; John T. Sinott, IV, MD; Joshua Weiss, BS; Douglas A. Holt, MD

Clinical Pharmacology of Antibiotics 319
Pharmacodynamic Properties of Antibiotics: Application to Drug Monitoring and Dosage Regimen Design
Steven C. Ebert, PharmD; William A. Craig, MD

Special Announcement 297
Preliminary Program of the Centers for Disease Control's Third Decennial International Conference on Nosocomial Infections, July 31-August 3, 1990

DEPARTMENTS

Information for Authors *274* ***SHEA Newsletter*** *327*

Letters to the Editor **279**

The ideas and opinions expressed by contributing authors do not necessarily reflect those of the editors or publisher.

Publisher: Infection Control and Hospital Epidemiology (ISSN-0899-823X) is published monthly by SLACK Incorporated 6900 Grove Road Thorofare New Jersey 08086 Telephone (609) 848-1000

Copyright 1990: All rights reserved No part of this publication may be reproduced without written permission from the publisher

Subscriptions: Requests should be addressed to the publisher (except Japan) In Japan, contact Woodbell Incorporated, 4-22-11, Kitakasai Edogawaku Tokyo 134 Japan Subscription rate:; in the US and possessions Individual One year—$60 00. Two years-$95 00. Three years—$125 00 Institutional One year—$70 00. Two years—$110 00 Three years—$150 00 Canada $18 00 additional each year all other countries $30 00 additional each year Single copies of current issues may be obtained for $8 00 United States and possessions $16 00 all other countries

Reprints: All requests to reprint or use material published herein should be addressed to Lester J Robeson, SLACK Incorporated 6900 Grove Road. Thorofare. NJ 08086 For reprint orders and prices, contact Fran Micaletti at (609) 848.1000 Authorization to photocopy items for internal or personal use or the internal or personal use of specific clients is granted by SLACK Incorporated provided that the base lee of $100 per copy, plus $ 15 per page is pad directly to Copyright Clearance Center, 27 Congress Street. Salem MA 01970 This consent does not extend lo other kinds of copying such as for general distribution resale advertising and promotional purposes, or for creating new collective works

Change of address: Notice should be sent to the publisher six weeks in advance of effective date Include old and new addresses with zip codes The publisher cannot accept responsibility for undelivered copies Second-class postage is paid at Thorofare, New Jersey 08086, and additional entry pants Postmaster: Send address changes to SLACK Incorporated. 6900 Grove Road Thorofare NJ 08086

As of Volume 1 Number 1 INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY is listed in *index Medicus, Current Contents—Clinical Practice, Hospital Literature Index Cumulative* Index *to Nursing* and Allied Hearth *Literature.* and Nursing *Abstracts*

https://doi.org/10.1086/646169 Published online by Cambridge University Press

EDITORIAL OFFICES
Vanderbilt University School of Medicine
A-1131 Medical Center North
Nashville, TN 37232-2637
(615) 343-1095; (615) 343-1882 (FAX)
Email: iche@mcmail.vanderbilt.edu

EDITOR
Michael D. Decker, MD, MPH
MANAGING EDITOR
Susan Cantrell
STATISTICAL EDITOR
Beverly G. Mellen, PhD
SENIOR ASSOCIATE EDITORS
C. Glen Mayhall, MD
Gina Pugliese, RN, MS
William Schaffner, MD
ASSOCIATE EDITORS
Donald A. Goldmann, MD
Didier Pittet, MD, MS
Andreas Widmer, MD, MS
SECTION EDITORS
Beyond Infection Control: The New Hospital Epidemiology
Bryan P. Simmons, MD
Stephen B. Kritchevsky, PhD
Memphis, Tennessee
Wing Hong Seto, MD
Hong Kong
Disinfection and Sterilization
William A. Rutala, PhD, MPH
Chapel Hill, North Carolina
Emerging Infectious Diseases
Larry J. Strausbaugh, MD
Portland, Oregon
Robert W. Pinner, MD
Atlanta, Georgia
From the Laboratory
Marcus Zervos, MD
Royal Oak, Michigan
Fred C. Tenover, PhD
Atlanta, Georgia
Information Management
John A. Sellick, DO
Buffalo, New York
The International Perspective
Mary D. Nettleman, MD, MS
Richmond, Virginia
Issues in Surgery
James T. Lee, MD, PhD
St. Paul, Minnesota
Medical News
Gina Pugliese, RN, MS
Chicago, Illinois
Martin S. Favero, PhD
Irvine, California
Practical Healthcare Epidemiology
Loreen A. Herwaldt, MD
Iowa City, Iowa
SHEA News
Murray D. Batt, MD
Clarksburg, West Virginia
Statistics for Hospital Epidemiology
David Birnbaum, PhD, MPH
Sidney, British Columbia, Canada
Topics in Long-Term Care
Philip W. Smith, MD
Omaha, Nebraska
Topics in Occupational Medicine
David Weber, MD, MPH
Chapel Hill, North Carolina

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY®

EDITORIAL ADVISORY BOARD

Jacques F. Acar, MD	Paris, France
J. Wesley Alexander, MD	Cincinnati, Ohio
Paul Arnow, MD	Chicago, Illinois
Graham A.J. Ayliffe, MD	Birmingham, United Kingdom
Neil L. Barg, MD	Yakima, Washington
Elizabeth Ann Bolyard, RN, MPH, CIC	Atlanta, Georgia
John M. Boyce, MD	Providence, Rhode Island
Professor Dr. Ilja Braveny	Munich, Federal Republic of Germany
Charles Bryan, MD	Columbia, South Carolina
Christian Brun-Buisson, MD	Creteil, France
Donald E. Craven, MD	Boston, Massachusetts
Sue Crow, MSN, RN, CIC	Shreveport, Louisiana
Franz Daschner, MD	Freiburg, Federal Republic of Germany
Leigh G. Donowitz, MD	Charlottesville, Virginia
Charles E. Edmiston, Jr., PhD	Milwaukee, Wisconsin
Theodore C. Eickhoff, MD	Denver, Colorado
Bruce Farber, MD	Manhasset, New York
Victoria J. Fraser, MD	St. Louis, Missouri
Peter C. Fuchs, MD, PhD	Black Butte, Oregon
Richard A. Garibaldi, MD	Farmington, Connecticut
Velvl Greene, PhD, MPH	Beer Sheva, Israel
Robert Gaynes, MD	Atlanta, Georgia
David W. Gregory, MD	Nashville, Tennessee
David K. Henderson, MD	Bethesda, Maryland
Peter N.R. Heseltine, MD	Los Angeles, California
Karen Hoffmann, RN, CIC, MS	Chapel Hill, North Carolina
Marguerite McMillan Jackson, RN, PhD	San Diego, California
Janine Jagger, MPH, PhD	Charlottesville, Virginia
William R. Jarvis, MD	Atlanta, Georgia
Douglas S. Kernodle, MD	Nashville, Tennessee
Robert H. Latham, MD	Nashville, Tennessee
Lewis B. Lefkowitz, MD	Nashville, Tennessee
Hsieh-Shong Leu, MD, MSc	Taipei, Taiwan
Jack Levy, MD	Brussels, Belgium
Victor Lorian, MD	Bronx, New York
Dennis G. Maki, MD	Madison, Wisconsin
Professor Dr. Walter Marget	Munich, Federal Republic of Germany
William J. Martone, MD	Bethesda, Maryland
Allison McGeer, MD	Toronto, Ontario, Canada
John E. McGowan, Jr., MD	Atlanta, Georgia
Jonathan L. Meakins, MD, DSc	Montreal, Quebec, Canada
Raf Mertens, MD	Brussels, Belgium
Robert R. Muder, MD	Pittsburgh, Pennsylvania
Joseph M. Mylotte, MD, CIC	Buffalo, New York
Lindsay Nicolle, MD	Winnepeg, Manitoba, Canada
Juhani Ojajärvi, MD	Helsinki, Finland
Michael T. Osterholm, PhD, MPH	Minneapolis, Minnesota
Jan Evans Patterson, MD	San Antonio, Texas
Sindy M. Paul, MD	Trenton, New Jersey
Michael A. Pfaller, MD	Iowa City, Iowa
Samuel Ponce de Leon, MD, MSc	Mexico City, Mexico
Isaam Raad, MD	Houston, Texas
Manfred L. Rotter, MD, DipBact	Vienna, Austria
Theodore Sacks, MD	Jerusalem, Israel
William E. Scheckler, MD	Madison, Wisconsin
Kent Sepkowitz, MD	New York City, New York
Denis Spelman, MD	Prahran Victoria, Australia
Michael L. Tapper, MD	New York, New York
Clyde Thornsberry, PhD	Brentwood, Tennessee
Professor Leonid P. Titov	Minsk, Republic of Belarus
Timothy R. Townsend, MD	Millwood, Virginia
Antoni Trilla, MD, PhD	Barcelona, Spain
Professor Wang Shu-Qun	Beijing, People's Republic of China
J. John Weems, Jr., MD	Greenville, South Carolina
Robert A. Weinstein, MD	Chicago, Illinois
Professor Dr. W. Weuffen	Greifswald, Federal Republic of Germany
Sergio B. Wey, MD	São Paulo, Brazil
Rebecca Wurtz, MD	Evanston, Illinois

SLACK Incorporated
6900 Grove Road
Thorofare, New Jersey 08086
(609) 848-1000

Vice President/Group Publisher
Richard N. Roash

Publisher
John C. Carter

Editorial Director
Jennifer Kilpatrick

Production Editor
Shirley P. Strunk, ELS

Assistant Editor
Eileen C. Anderer

Circulation Manager
Lester J. Robeson, CCCP

Production Director
Christine Malin

Production Coordinator
Joanne Patterson

Publishing Director/ Advertising
Wayne McCourt

Pharmaceutical Group Sales Director
Michael LoPresti

Advertising Sales Representative
Jennine Kane

Classified/Recruitment Sales Manager
Michele Burch

https://doi.org/10.1086/646169 Published online by Cambridge University Press

"Synergism..."

Synergism is the working relationship between two ingredients which results in performance superior to that achieved by each ingredient working separately.

Synergism is Sporicidin. Glutaraldehyde combined with an alkaline phenate system produces superior disinfecting properties.* Patented Sporicidin disinfects with substantually less glutaraldehyde than other products.

Synergism makes Sporicidin tuberculocidal in only ten minutes at room temprature, 68° F and above, when diluted 1:16. Other alkaline glutaraldehyde products cannot be diluted and/or require longer contact times with heating to 77°F.

Sporicidin fulfills the CDC definition of high level disinfection using the lowest concentration of glutaraldehyde... because of Synergism.

* *Journal of Clinical Microbiology, November 1985, p. 735 - 739*



Sporicidin INTERNATIONAL

12000 Old Georgetown Road, Rockville, Maryland 20847

https://doi.org/10.1086/646169 Published online by Cambridge University Press